[EN] PYRAZOLECARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM [FR] DERIVES D'ACIDE PYRAZOLECARBOXYLIQUE, LEUR PREPARATION, LES COMPOSITIONS PHARMACEUTIQUES EN CONTENANT
摘要:
Le N-pipéridino-5-(4-bromophényl)-1-(2,4-dichlorophényl)-4-éthylpyrazole-3-carboxamide, ainsi que ses sels et solvants, sont des antagonistes puissants des récepteurs cannabinoïdes CB1. Ils sont préparés en faisant réagir un dérivé fonctionnel de l'acide 5-(4-bromophényl)-1-(2,4-dichlorophényl)-4-éthylpyrazole-3-carboxylique avec de la 1-aminopipéridine, suivie éventuellement d'une salification.
Discovery of 2-[5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-ethyl-1H-pyrazol-3-yl]-1,5,5-trimethyl-1,5-dihydro-imidazol-4-thione (BPR-890) via an Active Metabolite. A Novel, Potent and Selective Cannabinoid-1 Receptor Inverse Agonist with High Antiobesity Efficacy in DIO Mice
摘要:
By using the active metabolite 5 as an initial template, further structural modifications led to the identification of the titled compound 24 (BPR-890) as a highly potent CB I inverse agonist possessing an excellent CB2/1 selectivity and remarkable in vivo efficacy in diet-induced obese mice with a minimum effective dose as low as 0.03 mg/kg (po qd) at the end of the 30-day chronic study. Current SAR studies along with those of many existing rimonabant-mimicking molecules imply that around the pyrazole C3-position, a rigid and deep binding pocket should exist for CB1 receptor. In addition, relative to the conventional carboxamide carbonyl, serving as a key hydrogen-bond acceptor during ligand-CB1 receptor interaction, the corresponding polarizable thione carbonyl might play a more critical role in stabilizing the Asp366-Lys192 salt bridge in the proposed CB1-receptor homology model and inducing significant selectivity for CB1R over CB2R.
Imidazol-4-one or imidazole-4-thione compounds of formula (I):
wherein X, R
1
, R
2
, R
3
, R
4
, R
5
, and R
6
are defined herein. Also disclosed is a method for treating a cannabinoid receptor-mediated disorder with these compounds.
[EN] PYRAZOLECARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] DERIVES D'ACIDE PYRAZOLECARBOXYLIQUE, LEUR PREPARATION, LES COMPOSITIONS PHARMACEUTIQUES EN CONTENANT
申请人:SANOFI SYNTHELABO
公开号:WO2000046209A1
公开(公告)日:2000-08-10
Le N-pipéridino-5-(4-bromophényl)-1-(2,4-dichloro phényl)-4-éthylpyrazole-3-carboxamide, ses sels et solvants sont des puissants antagonistes des récepteurs aux cannabinoïdes CB1. Ils sont préparés par réaction d'un dérivé fonctionnel de l'acide 5-(4-bromophényl)-1-(2,4-dichlorophényl)-4-éthylpyrazole-3-carboxylique avec la 1-aminopipéridine puis salification éventuelle.
Le N-pipéridino-5-(4-bromophényl)-1-(2,4-dichlorophényl)-4-éthylpyrazole-3-carboxamide, ainsi que ses sels et solvants, sont des antagonistes puissants des récepteurs cannabinoïdes CB1. Ils sont préparés en faisant réagir un dérivé fonctionnel de l'acide 5-(4-bromophényl)-1-(2,4-dichlorophényl)-4-éthylpyrazole-3-carboxylique avec de la 1-aminopipéridine, suivie éventuellement d'une salification.
Pyrazolecarboxylic acid derivatives, their preparation, pharmaceutical compositions containing them
申请人:Sanofi-Synthelabo
公开号:US06432984B1
公开(公告)日:2002-08-13
N-Piperidino-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxamide and its salts and solvates are powerful antagonists of the CB1 cannabinoid receptors. They are prepared by reacting a functional derivative of 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxylic acid with 1-aminopiperidine, optionally followed by salification.
Pyrazolecarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them
申请人:——
公开号:US20020188007A1
公开(公告)日:2002-12-12
N-Piperidino-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxamide and its salts and solvates are powerful antagonists of the CB
1
cannabinoid receptors. They are prepared by reacting a functional derivative of 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxylic acid with 1-aminopiperidine, optionally followed by salification.